Influence of paclitaxel therapy on expression of ßIII-Tubulin and Carbonic anhydrase IX proteins in chemically-induced rat mammary tumors

Hladová, Alena; Hodorová, Ingrid; Rybárová, Silvia; Mihálik, Jozef; Bobrov, Nikita; Solár, Peter; Benetinová, Zuzana; Mirossay, Ladislav

doi:10.2478/s11756-020-00496-w

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possibility of targeted therapy using survivin inhibitors is a great challenge for the future as the regulation of aberrant survivin activity represents great potential for improving cancer therapy. In relation to our previous results [44] and recent data, we can conclude that the increased expression of βIII-tubulin, CA IX, and survivn is associated, positively or negatively, with PTX and DOX resistance.…”

Section: Discussionsupporting

confidence: 85%

Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat

Pastornická

Rybárová

Drahošová

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Breast cancer is the most common cancer in females. The aim of this study was to determine the effect of paclitaxel (PTX) and doxorubicin (DOX) therapy on the βIII-tubulin, carbonic anhydrase IX (CA IX), and survivin expression in chemically-induced rat mammary tumors. Animals with induced mammary carcinogenesis were randomly divided into treatment groups and an untreated group. The total proportion of tumors, the proportion of carcinoma in situ (CIS), and invasive carcinoma (IC) were evaluated. Protein expression in tumor tissue was determined using IHC. Statistical analysis of the data, evaluated by Fisher-exact test and unpaired t-test. Significantly increased levels of proteins in the tumor cells were confirmed using the IHC method for all studied proteins. The expression of βIII-tubulin, CA IX, and survivin increased significantly after treatment with both cytostatics (PTX and DOX). Depending on the type of tumor, a significant increase in all proteins was observed in IC samples after PTX treatment, and CA IX expression after DOX treatment. In CIS samples, a significant increase of βIII-tubulin and survivin expression was observed after a DOX treatment. The results suggest that βIII-tubulin, survivin, and CA IX may be significant drug resistance markers and the clinical regulation of their activity may be an effective means of reversing this resistance.

show abstract

Section: Discussionsupporting

confidence: 85%